Supplemental Material for: Effectiveness and safety of atezolizumab plus bevacizumab combined with transarterial chemoembolization as conversion therapy for initially unresectable hepatocellular carcinoma in real-world clinical practice in China (TALENTRUE): a multicenter, retrospective, observational cohort study